drugset / Trial / NCT01513187
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Phase I / II, open, prospective, multicenter single-arm, Clinical Trial in two stages: in the first stage it will determine the optimal dose of the combination of pazopanib and interferon alfa-A2 in the treatment of patients with advanced renal carcinoma and a second stage that will determine the efficacy of this combination measured in terms of response rate.
Timeline
- Start
- 2011-07-11
- Primary completion
- 2015-12
- Completion
- 2019-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon alfa-2a | Protein / enzyme biologic | 3e+06 iu | — |
| Subject | Interferon alfa-2a | Protein / enzyme biologic | 6e+06 iu | — |
| Subject | Interferon alfa-2a | Protein / enzyme biologic | 9e+06 iu | — |
| Subject | Pazopanib | Small molecule | 400 mg | — |
| Subject | Pazopanib | Small molecule | 600 mg | — |
| Subject | Pazopanib | Small molecule | 800 mg | — |